News Releases

TAXIS Pharmaceuticals Publishes on FtzS Inhibitors in NATURE The Journal of Antibiotics

May 27, 2022Read More Download

TAXIS Pharmaceuticals Publishes on Efflux Pump Inhibitors in MDPI Journal Antibiotics

May 26, 2022Read More Download

TAXIS Pharmaceuticals appears in August special issue on Antibiotic Alternatives in ACS Infectious Diseases

August 13, 2021Read More Download

World Health Organization Names TAXIS’ TXA709 as One of Only 2 (out of 26) Antibacterials Meeting All Innovation Criteria

April 15, 2021Read More Download

TAXIS Pharmaceuticals appears in June special issue on Antibiotics in ACS Infectious Diseases

June 12, 2020Read More Download

TAXIS Pharmaceuticals appears in June issue of Nature BioPharma Dealmakers

June 1, 2020Read More Download

TAXIS Pharmaceuticals announces CARB-X award of $3.2 million, with potential for an additional $11.4 million, to develop Efflux Pump Inhibitors (EPIs), a new drug class to defeat multi-drug resistant infections

January 14, 2020Read More Download

TAXIS secures NIH Funding

June 17, 2019Read More Download

Gram-Positive Bacterial Infections Market to Observe Strong Development by 2020 | Newszak

September 24, 2018Read More Download

TAXIS Pharmaceuticals to Present Pipeline Update at Biotech in Europe Forum: President and CEO Gregory Mario to Highlight Progress in Antibiotic Drug Development Focusing on Efflux Pump Inhibition and Modulation of FtsZ and MreB Proteins

September 28, 2017Read More Download

FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic: Compound Named a Qualified Infectious Disease Product (QIDP) for Acute Bacterial Skin and Skin Structure Infections

September 7, 2016Read More Download

TAXIS PHARMACEUTICALS DEMONSTRATES SYNERGISTIC EFFICACY AGAINST MRSA AND LOW RESISTANCE FREQUENCY WITH TXA709/CEFDINIR COMBINATION: Poster Presentation at ICAAC 2015 Highlights Potential of TXA709, Both Alone and in Combination with Cefdinir, as Oral Antibiotic for Drug-Resistant S. aureus Infections

September 18, 2015Read More Download

TAXIS PHARMACEUTICALS DEMONSTRATES CLINICAL POTENTIAL OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE: Poster Presentation at ECCMID 2015 Highlights Unique Mechanism of Action and Potent Bactericidal Activity against MRSA Strains

April 27, 2015Read More Download

TAXIS acquires novel antimicrobial drug candidates from Biota

August 11, 2014Read More Download

TAXIS Pharmaceuticals Moves to High-Tech Business Incubator Developer of Novel Antibiotics Accepted at the Tech Centre of New Jersey

September 22, 2010Read More Download

Rutgers-UMDNJ License Agreement: September 4, 2009

September 4, 2009Read More Download